Extended-spectrum beta-lactamases: A brief clinical update

Pediatric Infectious Disease Journal

Volumn 30, Issue 12, 2011, Pages 1092-1093

  Malloy, Allison M W ^a   Campos, Joseph M ^b,c  

^a Vaccine Research Center   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

antibiotics; beta lactamase; ESBL; extended spectrum beta lactamase; Gram negative bacteria; treatment

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE CTX M; CEFAZOLIN; CEFOTAXIME; CEFPODOXIME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLAVULANIC ACID; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; IMIPENEM; MEROPENEM; MONOBACTAM DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULBACTAM; TAZOBACTAM; TETRACYCLINE DERIVATIVE; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; CATHETER INFECTION; ENZYME ACTIVITY; GRAM NEGATIVE BACTERIUM; HUMAN; INFECTION CONTROL; INFECTION RISK; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; BETA-LACTAMS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 81855185865     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31823c0e9d     Document Type: Review

References (14)

1. Bush K, et al. Epidemiological expansion and clinical challenges of new-lactamases . . . Annu Rev Microbiol. 2011;65:455-478.
2. Du Bois SK, et al. TEM-and SHV-derived extended-spectrum beta-lactamases . . . J Antimicrob Chemother. 1995;35:7-22.
3. Paterson DL, et al. Extended-spectrum-lactamases: a clinical update. Clin Microbiol Rev. 2005;18:657-686.
4. Hawkey PM, et al. The changing epidemiology of resistance. J Antimicrob Chemother. 2009; 64(suppl 1):i3-i10.
5. Falagas ME, et al. Extended-spectrum -lactamase-producing organisms. J Hosp Infect. 2009; 73:345-354.
6. Zaoutis TE, et al. Risk factors and outcomes of bloodstream infection caused by. Pediatrics. 2009;115:942-994.
7. Topaloglu R, et al. Risk factors in communityacquired urinary tract infections caused by ESBL. Pediatr Nephrol. 2010;25:919-925.
8. Peirano G, et al. Molecular characteristics of extended-spectrum beta-lactamase-producing . . . Int J Antimicrob Agents. 2010;36:19-23.
9. Rogers BA, et al. Escherichia coli O25b-ST131: a pandemic, multiresistant, communityassociated strain. J Antimicrob Chemother. 2011;66:1-14.
10. Alsterlund R, et al. Long-term carriage of extended-spectrum beta-lactamase-producing Escherichia coli. Scand J Infect Dis. In press.
11. Goddard S, et al. The efficacy of infection control interventions in reducing the incidence of extended-spectrumβ-lactamase-producing Enterobacteriaceae . . . Am J Infect Control. 2011;39:599-601.
12. Paterson DL, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamases. Clin Infect Dis. 2004;39:31-37. (Pubitemid 38879546)
13. Falagas ME, et al. Fosfomycin for the treatment of multidrug-resistant extended-spectrumβ-lactamase producing, Enterobacteriaceae . . . Lancet Infect Dis. 2010;10:43-50.
14. Kelesidis T, et al. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae . . . J Antimicrob Chemother. 2008;62:895-904.